Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB)
2023-03-03AlbertoEpsteinetal
四川生理科学杂志 2023年9期
Alberto L Epstein, et al.
The FDA has recently approved Krystal biotech's beremagene gep erpavec (B-ⅤEC, Ⅴyjuvek) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients. This represents a giant step, not only toward the treatment of this devastating disease, but also for the whole field of non-replicative (nr) recombinant HSⅤ-1 vectors for gene therapy. To view this Bench to Bedside, open or download the PDF.
杂志排行
四川生理科学杂志的其它文章
- 罗哌卡因复合舒芬太尼硬膜外麻醉在无痛分娩中的麻醉、镇痛作用分析
- “动物生理学”课程融入思政教育的实践与思考#
- The gut microbiota reprograms intestinal lipid metabolism through long noncoding RNA Snhg9
- Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves: a registry study
- PINK1, Keap1, and Rtnl1 regulate selective clearance of endoplasmic reticulum during development
- Will climate change amplify epidemics and give rise to pandemics